The US Federal Trade Commission's antitrust complaint against Reckitt Benckiser Group PLC for its promotion of Suboxone film (buprenorphine/naloxone) as less susceptible to accidental pediatric exposure than the tablet formulation shows the kind of product hopping behavior the agency may pursue in the future.
The agency has expressed interest in going after drug makers for so-called product hopping, in which a drug manufacturer tries to delay generic competition for a product about to go...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?